mda published following article kennedy disease researcher many know five questions sbma researcher diane merry diane merry associate professor thomas jefferson university philadelphia working identify therapeutic opportunities promote normal androgen receptor function preventing toxic effects polyglutamine expansion spinal bulbar muscular atrophy sbma glaxosmithkline merry test small molecule compounds activate enzyme called sirt cell mouse models sbma determine therapeutic potential please describe current research sbma many neurodegenerative diseases result protein misfolding accumulation due genetic environmental causes sbma one disease inherited adult onset neuromuscular disease caused expansion polyglutamine tract within androgen receptor related mechanistically neurodegenerative diseases caused polyglutamine expansion important feature sbma onset progression dependent binding androgenic hormones mutant receptor studies mouse cell models sbma reproduce androgen polyglutamine dependent nuclear aggregation seen patients well toxicity revealed mutant must modified addition acetyl groups aggregation toxicity moreover deacetylase sirt strongly neuroprotective cell models sbma neuroprotection largely depends upon ability remove acetyl groups mutant investigating therapeutic potential activating acetyl group removing enzyme sirt small molecule activators test compounds cell models ultimately mouse models sbma anticipate studies reveal new powerful opportunities therapeutic development sbma first mda grant i funded previously post doctoral fellow i started lab mda means tremendous amount me funded organization committed finding cure neuromuscular diseases inspired study sbma i come strong background training molecular genetics molecular pathophysiology i began study molecular basis disease short time genetic cause disease identified i studying sbma ever since time past years focus within sbma field important focus mutant androgen receptor protein effect polyglutamine expansion androgen receptor metabolism structure trafficking protein interactions turnover order identify therapeutic opportunities promote normal androgen receptor function preventing toxic effects polyglutamine expansion work funded grant designed currently effective therapy cure sbma thus effective therapy primary goal work work funded likely bring closer goal feel people impacted sbma hope respect research right know much disease process point time others identified disease targets therapeutic development i think therapy therapies within sight sbma foreseeable future work potential implications disease fields work implications diseases enzyme sirt neuroprotective although sirt target proteins may distinct identification small molecule activators sirt likely open possibilities using activators treat diseases